European Primary Care Cardiovascular Society

Summary | Practical management of cardiovascular risk: Lessons from latest diabetes trials

May 3, 2018 – Prof. Lars Rydén, MD

This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Summary | The cardiovascular challenge for primary care in diabetes

May 3, 2018 – Prof. Richard Hobbs, MD

This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Diabetes: How to reduce risk from a cardiovascular perspective?

July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents

Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents

Intensive BP treatment in T2DM patients on standard glycemic control associated with decreased CV risk

July 11, 2018 - Tsujimoto T and Kajio H. - Hypertension. 2018

In a subanalysis of the ACCORD BP trial, intensive blood pressure treatment in T2DM patients receiving standard glycemic control was significantly associated with a decreased risk of CV events, including HF hospitalization.

The cardiovascular challenge for primary care in diabetes

July 10, 2018 - Prof. Richard Hobbs - Oxford, UK
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Reduction of CVD with healthy lifestyle after diabetes diagnosis

July 3, 2018 - Liu G et al. - J Am Coll Cardiol 2018

Maintaining or changing to a healthy lifestyle after diabetes diagnosis is associated with a significantly lower risk CVD incidence and mortality.

PCSK9 inhibitor and statins highly effective in people with diabetes with ACS

June 25, 2018 - news

ADA 2018 Analysis of ODYSSEY OUTCOMES trial indicates people with diabetes and prior ACS benefit most from the combination of alirocumab and statins, compared to ACS survivors with prediabetes or with normal glucose levels

High CV risk in obese women even in the absence of metabolic abnormalities

June 13, 2018 - Eckel N, et al. - Lancet Diab Endocrin 2018

CV risk is high in obese women without metabolic abnormalities, as well as in women with hypertension, diabetes or hypercholesterolemia, independently of their body mass index.

What’s the evidence that diabetes is linked to CVD and an update on managing CV risk in diabetes

EPCCS CV Summit 2018

Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Prof. Xavier Cos, Barcelona, Spain
A recording of the lecture by Prof. Cos on the evidence fro diabetes and accelerated vascular disease, and which interventions can change this relationship.

EPCCS 2018 A recording of the lecture by Prof. Cos on the evidence fro diabetes and accelerated vascular disease, and which interventions can change this relationship.

Superior improvement of HbA1c with GLP-1 receptor agonist compared to SGLT2 inhibitor

May 30, 2018 - news

Results from the PIONEER 2 trial in T2DM patients demonstrated a significant and superior improvement in HbA1c with semaglutide compared to empagliflozin.

All-cause and CV mortality reduced by beta-blockers in non-diabetic and diabetic HF patients

May 29, 2018 - news
A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.

ESC HF 2018 A large study on individual patient data shows that diabetic HF patients who are not obese have the highest mortality. Obesity attenuates the prognostic impact of beta-blockers.